Skip to main content

Lucemyra Disease Interactions

There are 5 disease interactions with Lucemyra (lofexidine).

Major

Lofexidine (applies to Lucemyra) hypotension

Major Potential Hazard, Moderate plausibility. Applicable conditions: Cerebral Vascular Disorder, Myocardial Infarction, Renal Dysfunction, Heart Disease, Syncope

Lofexidine can cause a decrease in blood pressure, a decrease in pulse, and syncope. It is recommended to monitor vital signs before dosing and for symptoms related to bradycardia and orthostasis. If clinically significant or symptomatic hypotension and/or bradycardia occur, the next dose of lofexidine should be reduced in amount, delayed, or skipped. Avoid using lofexidine in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, chronic renal failure, and in patients with marked bradycardia.

References

  1. (2018) "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC
Moderate

Lofexidine (applies to Lucemyra) alcoholism

Moderate Potential Hazard, Moderate plausibility.

Lofexidine can potentiate the CNS depressive effects of alcohol and other CNS depressive substances. Care should be exercised when using this agent in patients with alcohol disorders.

References

  1. (2018) "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC
Moderate

Lofexidine (applies to Lucemyra) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Hepatic impairment slows the elimination of lofexidine, but exhibits less effect on the peak plasma concentration following a single dose. Dosage adjustments are recommended based on the degree of hepatic impairment. Close monitoring is recommended when using this agent in patients with hepatic impairment.

References

  1. (2018) "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC
Moderate

Lofexidine (applies to Lucemyra) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias, Electrolyte Abnormalities, Renal Dysfunction, Liver Disease

Lofexidine prolongs the QT interval. Its use should be avoided in patients with congenital long QT syndrome. It is recommended to monitor ECG prior to and during treatment in patients with congestive heart failure, bradyarrhythmias, hepatic impairment, renal impairment, or patients taking other medicinal products that lead to QT prolongation (e.g., methadone). Electrolyte abnormalities must be corrected prior to initiating therapy.

References

  1. (2018) "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC
Moderate

Lofexidine (applies to Lucemyra) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Renal impairment slows the elimination of lofexidine but exhibits less effect on the peak plasma concentration than on AUC values following a single dose. Dosage adjustments are recommended based on the degree of renal impairment. Only a negligible fraction of the lofexidine dose is removed during a typical dialysis session, so no additional dose needs to be administered after a dialysis session; therefore, the agent may be administered without regard to the timing of dialysis. Close monitoring is recommended when using this agent in patients with renal impairment.

References

  1. (2018) "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC

Lucemyra drug interactions

There are 548 drug interactions with Lucemyra (lofexidine).

Lucemyra alcohol/food interactions

There is 1 alcohol/food interaction with Lucemyra (lofexidine).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer